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Guidance for Clinical Laboratories Using FDA Authorized Diagnostic 
Assays for Ebola Virus Detection 
Introduction 
On October 25, 2014 the BioFire Defense “FilmArray Biothreat-E test” received Emergency Use 
Authorization (EUA) from the Food and Drug Administration (FDA) for the presumptive detection of 
Ebola Zaire virus in whole blood or undiluted urine specimens. Prior to this, the only diagnostic tests 
available in the U.S. were the Department of Defense (DoD) EZ1 Real-time RT-PCR Assay (FDA EUA 
August 5, 2014) performed in select State and Local Public Health Laboratory Response Network (LRN) 
Reference Laboratories, and CDC developed assays and confirmatory methods.  Two CDC developed 
assays, CDC Ebola Virus NP and VP40 Real-time RT-PCR Assays, received EUA on October 10, 2014. 
Several other companies are in different stages of completing their applications for EUA of a number of 
additional commercially available Ebola Virus Disease (EVD) assays.  
Clinical laboratories considering implementation of commercially available EVD assays must remember 
the importance of connecting with Public Health authorities whenever EVD is suspected, the regulatory 
requirements for verification of assay performance before utilization for patient testing and to consider 
the risk/benefit of using this assay in their laboratory. This document is intended to provide laboratories 
with information to guide decisions on whether to implement any of the EVD in-vitro diagnostic assays 
available to clinical laboratories under EUA and includes a recommended algorithm for testing to 
support clinical and public health management of persons suspected to be infected with ebola virus.  
Clinical laboratories must consult with state or local Public Health partners both prior to testing and 
after testing to report results (both negative and positive) and determine next steps.  
Considerations for Implementing Ebola Testing In Your Laboratory 
• Use of EVD in-vitro diagnostic assays available under EUA requires Notification of Public Health.   
“Notification of Public Health:  Local, state and national public health agencies (for example, 
county and state health departments or the U.S. Centers for Disease Control and Prevention 
(CDC) should be notified of any patient suspected to have Ebola Virus Disease (EVD). 
Confirmatory testing at the state/local public health laboratory or at CDC is necessary for 
positive detection results and may be necessary for negative detection results.  Laboratories 
should consult with local, state or national public health officials on any positive detection OR no 
detection EVD test result on the need for additional testing and appropriate transportation of 
specimens.” 
• In order to report patient results to clinicians and use results for patient management in 
compliance with the Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory 
Guidance for Clinical Laboratories Using FDA Authorized Diagnostic Assays for Ebola Virus 
Detection  
  
Improvement Amendments (CLIA) regulations, clinical laboratories are required to verify 
performance characteristics for the assay in their facilities.  Verification materials (e.g. 
inactivated RNA) are available for purchase from companies such as Biodefense and Emerging 
Infections (BEI) Resources.   However, the company may experience inventory issues due to high 
demand.  If verification of performance characteristics is not performed laboratories will not be 
in compliance with CLIA regulations.  
• Prior to implementing any assay, laboratories should conduct a Biosafety Risk Assessment to 
identify sources of risk and implement safety measures to mitigate them. Laboratories should be 
fully compliant with all recommended biosafety and personal protective equipment (PPE) 
standards and guidelines.  
• Carefully review the Ebola virus assay product to ensure a full understanding of the approved 
intended use of the assay, result interpretation criteria, warnings and limitations.  
• Laboratories should also be aware that Ebola virus is regulated as a select agent under federal 
regulations 42 CRF Part 73. The select agent regulations would not apply until the specimen that 
has tested presumptively positive using molecular methods has been proven to contain live-
infectious Ebola virus by virus isolation at CDC. Viral culture, including culture on any rapid 
culture systems, should NOT be attempted in a clinical laboratory, under any circumstances on 
any specimen from an Ebola virus suspect. Laboratories should exercise caution and ensure that 
all specimens associated with Ebola cases are appropriately monitored.  Upon successful 
isolation of Ebola virus at CDC, all primary specimens and samples at non select agent regulated 
laboratories must be transferred to a registered select agent facility or destroyed within 7 days.  
• The use of commercially available EVD assays under EUA is only authorized for use with 
specimens from individuals with signs and symptoms of Ebola virus infection in conjunction with 
epidemiologic risk factors.  These tests should not be used on patients that do not exhibit 
symptoms.  
• Although commercially available EVD assays may be authorized for specimen types other than 
blood, collection of blood specimens at the initiation of testing is recommended.  Blood 
specimens are required for confirmatory testing.  Therefore, the use of blood specimens 
throughout the testing algorithm will provide the most efficient turnaround time.  
• Test results are for the PRESUMPTIVE identification of Ebola Zaire virus. Confirmatory testing in 
consultation with public health authorities is required.  Negative results do NOT preclude Ebola 
Zaire infection and should not be used as the sole basis for patient management or isolation 
decisions.  
Additional Resources 
BioFire Defense FilmArray Biothreat-E test 
• Emergency Use Authorization 
https://www.federalregister.gov/articles/2014/08/12/2014-19026/declaration-regarding-
emergency-use-of-in-vitro-diagnostics-for-detection-of-ebola-virus  
• Package Insert 







• Checklist for Evaluating Patients Under Investigation 
 http://www.cdc.gov/vhf/ebola/pdf/checklist-patients-evaluated-us-evd.pdf 
• Algorithm for Evaluation of the Returned Traveler  
http://www.cdc.gov/vhf/ebola/pdf/ebola-algorithm.pdf 
 
Packaging and Shipping 




• Packaging and Shipping eLearning Course 
http://www.cdc.gov/labtraining/course_listing/packing_shipping.html 
Personal Protective Equipment 
• CDC Guidance on PPE 
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html 
Risk Assessment 
• Risk Assessment Template. While this template is designed for public health laboratories, clinical 
laboratories may find this tool useful in conducting risk assessment for their facilities. 
http://www.aphl.org/aphlprograms/preparedness-and-response/Documents/APHL-
Template.pdf 
Points of Contacts for Additional Questions 
• CDC Emergency Operations Center: 770-488-7100 
































Hospital Identifies Patient as Ebola Suspect Using CDC Guidance for Evaluating a Patient Under 
Investigation 
Clinical Laboratory or Hospital Notifies State or Local Public Health Department 
Confers with Public Health Experts to Determine Ebola Testing Needs 
 
Multiple Blood Specimens Collected and Transported to 
Clinical Laboratory  
Using Appropriate Biosafety Procedures Clinical Laboratory 
Packages and Ships Additional Specimens Using 
Appropriate Guidance to Designated Public Health LRN 
Reference Laboratory and/or CDC as Advised for Additional 
Testing.  
 
Clinical Laboratory Tests Patient Specimen 
 
Follows All Appropriate Biosafety Procedures as Identified 






State or Local Public 
Health Department in 
Consultation with CDC 
Determine Next Steps 
Clinical Laboratory Notifies State or Local Public Health 
Department and CDC of Positive Test Result 
Compare results with LRN Reference Laboratory or 
CDC results 
 
State or Local Public Health Department in 
Consultation with CDC Determine Next Steps  
State/ Local Public 
Health Department in 
Consultation with CDC 
Determine Next Steps. 
Retesting in 72 Hours 
May Be Indicated 
Clinical Laboratory Notifies State or Local 
Public Health Department and CDC of 
Negative Test Result. Compare results with 















1Information on Testing When Public Health Officials Determine It Is Not Indicated  
Testing performed on individuals who do not meet the intended use criteria as defined in FDA labeling 
or without consultation with public health is not advisable and carries inherent risk. 
• Testing outside the approved parameters of the EUA is considered to be a test modification and 
the laboratory performing the testing is responsible for establishing and assuring the safety and 
efficacy of the test in the patient population being tested (e.g. asymptomatic individuals). 
• A positive result in a patient who is at low risk for EVD may be a false positive and can cause 
undue public health concern. 
• Patients without symptoms but with risk factors for EVD who are tested outside the 
recommended parameters of the assay may be overly assured by a negative result and not 
comply with federal or state Movement and Monitoring requirements or seek medical care if 
symptoms develop. 
• Individuals with a travel history to West Africa may be at risk for other infectious diseases 
including malaria and other viral hemorrhagic diseases (Lassa Fever, Marburg).  All risk factors 











This publication was supported by Cooperative Agreement # U60HM000803 funded by the Centers for Disease Control and 
Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC or 
the Department of Health and Human Services. National Center for Immunization and Respiratory Diseases (IP)Office of 
Surveillance, Epidemiology and Laboratory Services (OSELS)National Center for HIV, Viral Hepatitis, STDs and TB Prevention 
(PS)National Center for Zoonotic, Vector-borne, and Enteric Diseases (CK)National Center for Environmental Health 
(NCEH)Coordination Office for Terrorism Preparedness and Emergency Response (CTPER) 
